Prostate Cell News Volume 9.29 | Aug 3 2018

TOP STORY

Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis

Scientists identified a binding interaction between ERG and the mammalian SWI/SNF (BAF) ATP-dependent chromatin remodeling complex, which is conserved among other oncogenic ETS factors, including ETV1, ETV4, and ETV5. In a prostate organoid model, BAF complexes were required for ERG-mediated basal-to-luminal transition, a hallmark of ERG activity in prostate cancer. [Mol Cell] Abstract | Graphical Abstract | Press Release

(Ranked by impact factor of the journal)

KDM8/JMJD5 as a Dual Coactivator of AR and PKM2 Integrates AR/EZH2 Network and Tumor Metabolism in CRPC

Investigators showed that KDM8’s oncogenic properties in prostate cancer came from its direct interaction with androgen receptor (AR) to affect androgen response and with pyruvate kinase M2 (PKM2) to regulate tumor metabolism. The interaction with AR lead to the elevated expression of androgen response genes in androgen-deprived conditions. [Oncogene] Full Article

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Pre-Clinical Models of Prostate Cancer

MEDI3726 demonstrated potent and specific cytotoxicity in a panel of prostate specific membrane antigen (PSMA)-positive prostate cancer cell lines, consistent with internalization and DNA interstrand crosslinking. MEDI3726 also demonstrated durable antitumor activity in the PSMA-positive human prostate cancer patient-derived xenograft LuCaP models. [Mol Cancer Ther] Abstract

A Natural Molecule, Urolithin A, Downregulates Androgen Receptor Activation and Suppresses Growth of Prostate Cancer

Treatment with urolithin A (UroA) inhibited cell proliferation in both androgen receptor-positive (AR⁺) and androgen receptor-negative (AR^–) cells however, AR⁺ CaP cells were more sensitive to UroA treatment as compared with AR^– CaP cells. [Mol Carcinog] Abstract

Polyacetal-Based Combination Therapy for the Treatment of Prostate Cancer

The drug ratio was optimized to achieve anticancer drug synergism with elevated cytotoxicity against LNCaP-hormone-dependent human prostate cancer cells conferred via the induction of S phase cell cycle arrest by the upregulation of p53 and CDK inhibitors p21Waf/CIP1 and downregulation of cyclin D1. [Macromol Rapid Commun] Abstract

The Transcriptional Factor ZEB1 Represses Syndecan 1 Expression in Prostate Cancer

Researchers demonstrated that SNAIL, SLUG and ZEB1 expressions were increased in advanced prostate cancer, contrarily to syndecan 1 (SDC-1). SNAIL, SLUG and ZEB1 also showed an inversion to SDC-1 in prostate cell lines. ZEB1, but not SNAIL or SLUG, repressed SDC-1 as demonstrated by experiments of ectopic expression in epithelial prostate cell lines. [Sci Rep] Full Article

Chronic Hypoxia-Induced Slug Promotes Invasive Behavior of Prostate Cancer Cells by Activating Expression of Ephrin-B1

The authors found that an epithelial-mesenchymal transition (EMT)-driving transcription factor Slug was specifically up-regulated under chronic hypoxia and promoted tumor cell migration and invasion. Unexpectedly, processes associated with EMT, such as loss of E-cadherin, were not observed under chronic hypoxia. [Cancer Sci] Abstract

Bisphenol-A and Nonylphenol Induce Apoptosis in Reproductive Tract Cancer Cell Lines by the Activation of ADAM17

Investigators showed that bisphenol A and nonylphenol induced apoptosis in prostate and ovary cancer cell lines, in a process dependent on A Disintegrin And Metalloprotease 17 (ADAM17) activation. ADAM17 knockdown completely prevented apoptosis as well as the shedding of ADAM17 substrates. [Int J Mol Sci] Full Article

Androgen Receptor Degradation by the Proteolysis-Targeting Chimera ARCC-4 Outperforms Enzalutamide in Cellular Models of Prostate Cancer Drug Resistance

ARCC-4 inhibited prostate tumor cell proliferation, degraded clinically relevant androgen receptor point mutants and unlike enzalutamide, retained antiproliferative effect in a high androgen environment. [Commun Biol] Full Article

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Landmarks in Prostate Cancer

Advances in the understanding of the epidemiology, natural history, anatomy, detection, diagnosis, grading, staging, imaging, and management of prostate cancer have changed clinical practice and influenced guideline recommendations. Ongoing research and clinical trials are expected to yield more practice-changing results in the near future. [Nat Rev Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute

Under the agreement, Dana-Farber researchers were, and will continue to be, granted permission to conduct independent pre-clinical and clinical studies on select Lilly compounds. All compounds evaluated through this collaboration will continue to be fully owned by Lilly. Financial terms of the agreement were not disclosed. [Eli Lilly and Company] Press Release

The Prostate Cancer Foundation Appoints Christine Jones as Chief Operating Officer

The Prostate Cancer Foundation announced that Christine Jones has been appointed Chief Operating Officer effective immediately reporting to Jonathan W. Simons, MD, President and Chief Executive Officer. [Prostate Cancer Foundation] Press Release

Gigantic Review of German Science Recommends More Data and Diversity

Germany’s largest research organization is funding top-notch science, but it needs to employ more foreign and female researchers — and it is failing to leverage ‘big data’, such as electronic medical records. [Nature News] Editorial

Brexit Preparedness: EMA to Further Temporarily Scale Back and Suspend Activities

The European Medicines Agency (EMA) will launch the next phase of its business continuity plan on 1 October 2018 at the latest. This will allow the Agency to safeguard core activities related to the evaluation and supervision of medicines, while it has to intensify its preparations for the physical move to Amsterdam in March 2019 and cope with significant staff loss. [European Medicines Agency] Press Release

Trump’s Pick to Head White House Science Office Gets Good Reviews

The long wait for a White House science adviser is over. President Donald Trump announced that he intends to nominate meteorologist Kelvin Droegemeier, a university administrator and former vice-chair of the governing board of the U.S. National Science Foundation, to be director of the White House Office of Science and Technology Policy. [ScienceInsider] Editorial

NEW 2019 World Stem Cell Summit
January 22-25, 2019
Miami, Florida, United States

Visit our events page to see a complete list of events in the community.

NEW Research Fellow – Personalized Medicine of Anti-Cancer Therapy (Mayo Clinic)

NEW Senior Research Scientist – Prostate Cancer Research (University of California, San Francisco)

NEW Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities)

Clinical Fellow – Prostate Cancer Biology (Cancer Research UK Manchester Institute)

Assistant or Associate Professor – Prostate Cancer (Lerner Research Institute of the Cleveland Clinic)

Postdoctoral Position – Tumor Ecosystem Research (University of Zurich)

Postdoctoral Felllow – Non-Coding RNA & Cancer Research (Universtiy of Toronto)

Research Fellowship – Prostate Cancer Pathology (Weill Cornell Medicine)

Postdoctoral Fellow – Prostate Cancer Metastasis Research (Oregon Health & Science University)

Postdoctoral Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

Postdoctoral Fellow – Prostate Cancer Development & Progression Research (Brigham & Women’s Hospital-Harvard Medical School)

Postdoctoral Positions – Ribosome Modifications (University of Copenhagen)

Research Fellow – Prostate Cancer (Sechenov University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.